Ridgemont Acquires BioPharma Co

Noto, Anthony
May 2011
Mergers & Acquisitions Report;5/23/2011, Vol. 24 Issue 21, p8
The article reports on the acquisition of a majority stake in Gallus Biopharmaceuticals LLC by U.S. finance firm Ridgemont Equity Partners. It mentions that the price of the deal ranges between 25 million to 75 million U.S. dollars. According to the author, the contract is essential to the establishment of Gallus' manufacturing plant which Johnson & Johnson plans to buy.


Related Articles

  • Middle-Market M&A on the Rise. Tarbous, Ken // Mergers & Acquisitions Report;9/20/2010, Vol. 23 Issue 38, p33 

    The article discusses the state of mergers and acquisitions as of September 20, 2010. It was observed that Ridgemont Equity Partners has completed many acquisitions of companies with sales prices ranging from 10 to 100 million U.S. dollars. Sponsors are reportedly spending more for...

  • Ridgemont Equity Loads Unishippers Global Logistics Deal. Diakantonis, Demitri // Mergers & Acquisitions Report;10/20/2015, p2 

    The article discusses the plan of Ridgemont Equity Partners for acquiring logistics provider Unishippers Global Logistics to enhance its service offerings, and also mentions the views of Unishippers president Kevin Lathrop on the acquisition deal.

  • Genstar Capital Combines ISqFt & BidClerk to Form Construction Software Co. Collins, Allison // Mergers & Acquisitions Report;10/13/2014, Vol. 29 Issue 50, p1 

    The deal follows acquisitions in the building products sector by Symphony Technology, Audax and Ridgemont Equity

  • Cross River Fiber receives investment. Hawkes, Alex // Capacity Magazine;3/16/2015, p1 

    Private equity firm Ridgemont Equity Partners has acquired a majority interest in US dark fibre provider Cross River Fiber.

  • Ridgemont Completes Unite Deal. Cody, Tamika // Mergers & Acquisitions Report;12/20/2010, Vol. 23 Issue 51, p23 

    The article reports that Unite Private Networks has been completely acquired by Ridgemont Equity Partners.

  • A peek inside Guidant-J&J-Boston Scientific drama. Andrews, Greg // Indianapolis Business Journal;12/19/2005, Vol. 26 Issue 42, p4 

    The article looks into the high profile competitive bids between Johnson & Johnson with Boston Scientific Corp. for the control of Guidant Corp. in the U.S. Negotiations for the consolidation and merger of Guidant have been intense. The highlights of the negotiation between Boston Scientific...

  • Boston Scientific bids $25B for Guidant. Donhardt, Tracy // Indianapolis Business Journal;12/12/2005, Vol. 26 Issue 40, p35 

    The article focuses on the 25 billion-dollar bid of Boston Scientific Corp to purchase Guidant Corp. stocks in Indiana. Boston Scientific is now competing with Johnson & Johnson for stock purchase negotiation. The terms and provisions of the revised merger agreements of both companies are presented.

  • Guidant's woes turn J&J dead into game of chance. Andrews, Greg // Indianapolis Business Journal;7/4/2005, Vol. 26 Issue 17, p4A 

    Comments on the sale of Guidant Corp. at a low price to Johnson & Johnson in the U.S. Explanation of Guidant CEO Ron Dollens about the reason for accepting the low value of the company's share; Impact of the announcement of Guidant to pull five types of heart defibrillators on its share price;...

  • J&J plans to buy Mentor in $1B cash tender deal.  // Medical Technology & Devices Week;12/8/2008, Vol. 6 Issue 49, p3 

    The article reports that Johnson & Johnson (J&J) will be acquiring aesthetic medicine supplier, Mentor for a cash tender offer of $1.07 billion. The entry notes that J&J's tender offer is conditioned on a majority of outstanding shares of Mentor's common stock on a fully diluted basis. J&J's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics